Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

Jul 20, 2017

|

This article has been updated to include additional comments from Abbott's earnings call.

NEW YORK (GenomeWeb) – Abbott today said that its Diagnostics business grew sales 4 percent year over year in the second quarter, driven in part by strong growth in for its core laboratory and point-of-care tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

What's Popular?

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Cellex, Gauss Partner on At-Home, Point-of-Care Coronavirus Antigen Test

Fulgent Genetics Wins Utah COVID-19 Testing Contract

Sponsorships